In the dynamic world of pharmaceutical manufacturing, Patheon has emerged as a significant player, particularly in the softgel capsule market. This comprehensive analysis delves into Patheon's market position, strengths, and strategic insights within the competitive landscape of softgel manufacturing.
The Softgel Market: An Overview
The global softgel capsules market is experiencing robust growth, with a valuation of USD 1.1 Billion in 2022 and projected to reach USD 1.9 Billion by 2032, growing at a CAGR of 6.0%[2]. This growth is driven by several factors, including consumer preference for easy-to-swallow dosage forms and the ability of softgels to mask unpleasant tastes and odors of pharmaceuticals[2].
Patheon's Market Position
Patheon, now a part of Thermo Fisher Scientific following a $7.2 billion acquisition in 2017[7], has established itself as a leading contract development and manufacturing organization (CDMO) in the pharmaceutical industry. The company's softgel capabilities have significantly contributed to its strong market position.
Key Statistics:
- Patheon has developed and manufactured 20% of the top 100 drugs and 75% of the dosage forms on the market over the past decade[9].
- The company employs 8,700 people, including over 600 scientists, across 25 locations globally[9].
- Patheon has provided development and manufacturing services for approximately 400 clients, covering more than 700 products and molecules[9].
Patheon's Softgel Capabilities
Patheon's softgel offerings are comprehensive and technologically advanced, positioning the company as a preferred partner for pharmaceutical companies seeking innovative drug delivery solutions.
Manufacturing Capacity
"We bring decades of experience from development through commercialization and have dedicated encapsulation facilities in High Point, NC, and Tilburg, the Netherlands, have the capacity to produce 10 billion to 12 billion softgels annually."[1]
This substantial manufacturing capacity allows Patheon to meet the demands of both large-scale commercial production and smaller, specialized runs.
Innovative Technologies
Patheon offers a range of proprietary softgel technologies, each designed to address specific pharmaceutical challenges:
- Soft Lozenge Technology: Improves patient compliance with a soft, soothing mouthfeel[1].
- Chewels™: Chewable gels ideal for pediatric and geriatric populations[1].
- EnteriCare™: Incorporates enteric properties directly into the gelatin shell, eliminating extra coating steps[1].
- Liquisoft™: Soft-chewable shell suitable for liquid fills requiring fast onset of action[1].
- Sofgels™: Suitable for liquid formulations and applications requiring faster onset of action[1].
- Soflet™ Gelcaps: Employs gelatin-enrobing technology to make tablets easier to swallow[1].
- Versatrol™: Controlled release softgels with tamper-resistant technology[1].
These innovative technologies demonstrate Patheon's commitment to addressing diverse pharmaceutical needs and enhancing drug delivery efficacy.
Strategic Partnerships and Acquisitions
Patheon has strategically expanded its softgel capabilities through partnerships and acquisitions:
PROCAPS Partnership
In 2012, Patheon entered into an exclusive partnership with PROCAPS S.A., a Colombian-based softgel manufacturer[3]. This partnership, branded as "P-Gels," gave Patheon rights to market PROCAPS' softgel technology and manufacturing capabilities in North America, Europe, and Asia[3].
"This exclusive agreement is part of our recently announced strategy to strengthen our core operations and product offerings," said Jim Mullen, Patheon's Chief Executive Officer[3].
This partnership significantly expanded Patheon's softgel capabilities, adding capacity to manufacture up to nine billion capsules per year[3].
Thermo Fisher Scientific Acquisition
The acquisition of Patheon by Thermo Fisher Scientific in 2017 for $7.2 billion marked a significant milestone in Patheon's growth trajectory[7]. This acquisition has likely enhanced Patheon's resources and market reach, further solidifying its position in the softgel market.
Market Strengths and Competitive Advantages
Patheon's strengths in the softgel market are multifaceted:
-
Technological Innovation: Patheon's diverse range of proprietary softgel technologies positions it as an innovator in the field.
-
Manufacturing Capacity: With the ability to produce 10-12 billion softgels annually, Patheon can meet large-scale production demands[1].
-
Global Presence: Operating in 25 locations across Europe, North America, Australia, and Asia, Patheon has a strong global footprint[9].
-
Expertise: The company's experience in developing and manufacturing 20% of the top 100 drugs showcases its pharmaceutical expertise[9].
-
Comprehensive Services: Patheon offers end-to-end services from early development to commercial production, making it a one-stop solution for pharmaceutical companies[9].
Strategic Insights and Future Outlook
As the softgel market continues to grow, Patheon is well-positioned to capitalize on several trends:
Focus on Bioavailability
With 70% of drugs in development facing solubility issues, Patheon's expertise in developing softgel formulations to overcome bioavailability challenges is a significant asset[1].
Lifecycle Management
Patheon's capabilities in developing softgel formulations for late-stage lifecycle management can help clients retain market share and maximize product lifetime value[1].
Expansion in Emerging Markets
The Asia Pacific region is expected to grow at the fastest CAGR of 8.6% in the softgel market[5]. Patheon's global presence positions it well to tap into this growth.
Focus on Nutraceuticals
The nutraceutical companies segment dominated the softgel market with a 37.7% revenue share in 2022[5]. Patheon's diverse softgel technologies are well-suited to meet the growing demand in this sector.
Challenges and Competition
Despite its strong position, Patheon faces competition from other major players in the softgel market:
- Capsugel held a 43.0% market share in 2017[10].
- Catalent Inc. and Patheon NV followed with 15.4% and 4.2% market shares, respectively[10].
To maintain and improve its market position, Patheon will need to continue innovating and expanding its capabilities.
Key Takeaways
-
Patheon, now part of Thermo Fisher Scientific, is a major player in the softgel capsule market, with significant manufacturing capacity and innovative technologies.
-
The global softgel market is growing rapidly, projected to reach USD 1.9 Billion by 2032, presenting significant opportunities for Patheon.
-
Patheon's strengths include its technological innovation, manufacturing capacity, global presence, and comprehensive service offerings.
-
Strategic partnerships and acquisitions, such as the PROCAPS partnership and Thermo Fisher acquisition, have enhanced Patheon's market position.
-
Future growth opportunities lie in addressing bioavailability challenges, lifecycle management, expansion in emerging markets, and the nutraceutical sector.
-
Despite strong competition, Patheon's diverse capabilities and global reach position it well for continued growth in the softgel market.
FAQs
-
What is Patheon's annual softgel manufacturing capacity?
Patheon has the capacity to produce 10 billion to 12 billion softgels annually at its dedicated encapsulation facilities in High Point, NC, and Tilburg, the Netherlands.
-
How has the acquisition by Thermo Fisher Scientific impacted Patheon's market position?
The $7.2 billion acquisition in 2017 has likely enhanced Patheon's resources and market reach, further solidifying its position in the softgel market.
-
What are some of Patheon's innovative softgel technologies?
Patheon offers several proprietary technologies including Chewels™, EnteriCare™, Liquisoft™, Sofgels™, Soflet™ Gelcaps, and Versatrol™, each designed to address specific pharmaceutical challenges.
-
How is Patheon positioned to address the growing nutraceutical market?
Patheon's diverse softgel technologies and manufacturing capabilities are well-suited to meet the growing demand in the nutraceutical sector, which dominated the softgel market with a 37.7% revenue share in 2022.
-
What is the projected growth of the global softgel capsules market?
The global softgel capsules market is expected to grow from USD 1.1 Billion in 2022 to USD 1.9 Billion by 2032, at a CAGR of 6.0%.
Sources cited:
- https://www.patheon.com/us/en/our-capabilities/small-molecule/softgels.html
- https://www.futuremarketinsights.com/reports/softgel-capsules-market
- https://www.biospace.com/patheon-adds-soft-gel-capsule-capabilities-through-new-partnership-with-procaps-s-a
- https://www.grandviewresearch.com/industry-analysis/softgel-capsules-market-report
- https://www.dcatvci.org/features/thermo-fisher-s-7-2-billion-buy-of-patheon-the-implications-for-the-cdmo-market/
- https://www.pharmaceutical-technology.com/contractors/contract-manufacturers/patheon-inc/
- https://www.marketresearchfuture.com/reports/softgel-capsule-market/market-size
